Initial research indicates that PerinelineTM, which received Orphan Drug Designation in 2022 may improve neuroplasticity and neuroregeneration to enable new synapses to be made. Pre-clinical data indicates that the therapy may improve mobility in both acute and chronic cases.
In partnership with AscellaHealth, NeuroSolv Therapeutics is seeking to expand the clinical trial development programme and accelerate regulatory approval procedures to optimise the prospect of bringing PerinelineTM to market.
Initial data from pre-clinical trials on PerinelineTM, developed by NeuroSolv Therapeutics, indicates that it may improve mobility and be used in both chronic and acute cases.
The non-surgical, medical therapy which has attained European Medicines Agency (EMA) Orphan Designation, has a proposed mechanism of action that may improve both neuroplasticity and neuroregeneration.
By temporarily removing the protective perineuronal net on the surface of spinal cord neurons, new synapses can be created. When combined with rehabilitation techniques, this process enables new connections to be made to enable functional recovery. In addition, the treatment removes signal-blocking glial scars on the surface of spinal cord neurons to enable new synapses to be made.
The grounding research of highly regarded neuro glyco scientist, Dr. Jessica Kwok, indicates that Perineline™, the new therapy developed by the NeuroSolv Therapeutics team may potentially improve mobility when administered at any point following injury. This would be a significant development in terms of spinal cord injury therapy. It would mean that the treatment could be given to acute as well as chronic cases of spinal cord injured patients, potentially even if it has been years since their initial injury.
The two-part treatment, an oral medication combined with neural signalling interventions, is well tolerated and does not require injections, surgery, or implants.
The treatment is about to undergo clinical trials and if regulatory approval is obtained, PerinelineTM could be used to treat up to two million patients with spinal cord injuries worldwide. Data shared by the World Health Organization indicates that globally between 250,000 and 500,000 people are injured or diagnosed with a spinal cord injury each year. Within the UK alone, there are 50,000 people living with a life-changing spinal cord injury acc